Telix Pharmaceuticals Ltd competitors & alternatives

PENTIXAPHARM HLDGPTP · PharmaceuticalsGermany

71% matchPublic

Similar pharmaceuticals company

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical company that develops first-in-class radiopharmaceutical diagnostics and therapeutics, focusing on CXCR4-targeted compounds. The company serves patients and healthcare providers by advancing drug candidates through clinical trials, including Phase III-ready programs.

radiopharma rival LantheusBiotechnology & Pharmaceuticals

71% match

Biotechnology & Pharmaceuticals

Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.

Biotechnology & Pharmaceuticals

Cancer Research Horizons is a specialist drug discovery, development, and commercialisation company that translates lab-bench innovations into diagnostics and treatments for cancer patients. The company collaborates with researchers, partners, and investors to advance oncology therapeutics, manage start-ups, and license research tools and data portfolios.

Similar pharmaceuticals company

Advanced Accelerator Applications (AAA) is a French pharmaceutical company focused on molecular nuclear medicine, developing and manufacturing radiopharmaceuticals for diagnosis and targeted cancer treatment. Its products include Lutathera and diagnostic agents such as NETSPOT, serving oncology and nuclear-medicine clinicians and patients; AAA was acquired by Novartis in 2018.

Radiopharm Theranostics LtdRADX · BiotechCarlton, Australia

75% matchPublic

Biotech

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

Newrite MedicalMedical Technology

67% match

Medical Technology

Newrite Medical is a developer of targeted therapeutic and diagnostic agents for nuclear medicine applications. The company provides radiopharmaceutical development, isotope production, and radioligand therapy technologies.

Healthcare

PD Theranostics, Inc. (operating as United Theranostics) provides molecular imaging and precision radiopharmaceutical therapy for cancer patients, specializing in treatments for prostate cancer, neuroendocrine tumors, and thyroid cancer. The company utilizes advanced diagnostics such as PET and SPECT scans combined with targeted radiopharmaceuticals to deliver personalized, outpatient treatment plans. Additionally, they participate in clinical trials and collaborate with referring providers to offer innovative cancer care options.

ITM Isotope Technologies Munich SEBiotechnologyGermany

66% match

Biotechnology

ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company based in Garching bei München, Germany. It develops, produces, and globally supplies targeted radiotherapeutic and diagnostic agents for cancer treatment. The company notably secured a major €255 million investment round to further advance its clinical pipeline.

AVACTA GROUP PLCAVCT · BiotechAtlanta, United Kingdom

64% matchPublic

Biotech

Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.

Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Pharmaceuticals, Biotechnology & Life Sciences

Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.

ISLAND PHARMACEUTICALS LIMITEDILA · Pharmaceuticals, Biotechnology & Life SciencesHawthorn East, Australia

68% matchPublic

Pharmaceuticals, Biotechnology & Life Sciences

Island Pharmaceuticals Ltd is an Australian antiviral drug development company based in Melbourne, Australia, focused on addressing infectious diseases.